PubRank

L Kappos

Author PubWeight™ 152.94‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011 4.25
2 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009 3.37
3 Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008 3.28
4 MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial. Neurology 2010 2.33
5 Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 2011 2.26
6 The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007 2.17
7 FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 2008 2.07
8 Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry 1991 2.05
9 Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology 2010 2.04
10 Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. Proc Natl Acad Sci U S A 1990 1.93
11 Self glycolipids as T-cell autoantigens. Eur J Immunol 1999 1.93
12 MRI criteria for MS in patients with clinically isolated syndromes. Neurology 2010 1.90
13 A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 2002 1.86
14 Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. Neurology 2011 1.83
15 Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 2009 1.78
16 Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology 2011 1.75
17 Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J Clin Invest 1993 1.73
18 The alphabeta T cell response to self-glycolipids shows a novel mechanism of CD1b loading and a requirement for complex oligosaccharides. Immunity 2000 1.72
19 The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue. Mult Scler 2009 1.65
20 Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler 2009 1.65
21 Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study. Eur J Neurol 2008 1.63
22 Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology 1990 1.61
23 Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res Brain Res Rev 2001 1.59
24 Computer assisted retraining of attentional impairments in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 1998 1.57
25 MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007 1.56
26 Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology 1997 1.55
27 Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology 2003 1.54
28 Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology 2008 1.53
29 The challenge of follow-on biologics for treatment of multiple sclerosis. Neurology 2009 1.49
30 Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008 1.48
31 Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology 2007 1.45
32 The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain 2000 1.35
33 MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology 2006 1.29
34 Can the Expanded Disability Status Scale be assessed by telephone? Mult Scler 2003 1.28
35 Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis. Eur J Neurol 2009 1.27
36 Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology 2011 1.25
37 MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler 2006 1.25
38 Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology 1995 1.19
39 Black holes in multiple sclerosis: definition, evolution, and clinical correlations. Acta Neurol Scand 2009 1.17
40 Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 1998 1.15
41 Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol 2002 1.10
42 A knowledge-driven interaction analysis reveals potential neurodegenerative mechanism of multiple sclerosis susceptibility. Genes Immun 2011 1.08
43 Predictors of relapse rate in MS clinical trials. Neurology 2005 1.06
44 MR imaging in multiple sclerosis: review and recommendations for current practice. AJNR Am J Neuroradiol 2009 1.05
45 Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Mult Scler 2013 1.05
46 Fatigue in multiple sclerosis: relation to depression, physical impairment, personality and action control. Mult Scler 2007 1.05
47 Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial. Neurology 2012 1.05
48 Impairment of movement-associated brain deactivation in multiple sclerosis: further evidence for a functional pathology of interhemispheric neuronal inhibition. Exp Brain Res 2008 1.04
49 Anterior pituitary axis hormones and outcome in acute ischaemic stroke. J Intern Med 2011 1.03
50 Serial proton MR spectroscopy of contrast-enhancing multiple sclerosis plaques: absolute metabolic values over 2 years during a clinical pharmacological study. AJNR Am J Neuroradiol 2000 1.02
51 Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis. Neurology 2006 1.01
52 Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS. Neurology 2001 1.01
53 Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a. Neurology 2005 1.01
54 Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study. Mult Scler 2011 0.99
55 Magnetic resonance imaging and early diagnosis of multiple sclerosis. Lancet 1988 0.99
56 [Facial myokymia caused by pontine lesions and central fever in multiple sclerosis--case report]. Schweiz Rundsch Med Prax 1991 0.98
57 Reproducibility of fMRI in the clinical setting: implications for trial designs. Neuroimage 2008 0.98
58 Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis. Neuroradiology 2010 0.97
59 The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain 2001 0.97
60 Dynamic susceptibility contrast MR imaging of plaque development in multiple sclerosis: application of an extended blood-brain barrier leakage correction. J Magn Reson Imaging 2000 0.97
61 Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration. Mult Scler 2013 0.97
62 Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks. Mult Scler 2010 0.94
63 Stress hormones predict cerebrovascular re-events after transient ischemic attacks. Neurology 2011 0.94
64 MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN beta-1b. Neurology 2003 0.93
65 Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. Acta Neurol Scand 2013 0.93
66 BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. J Neurol 2010 0.92
67 Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life. Neurology 2001 0.92
68 Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome. Neurology 2011 0.91
69 Interferon β-1b and glatiramer acetate effects on permanent black hole evolution. Neurology 2011 0.91
70 Visual and motor evoked potentials in the course of multiple sclerosis. Brain 2001 0.90
71 Prediction of long-term disability in multiple sclerosis. Mult Scler 2011 0.90
72 Short-term adaptation to a simple motor task: a physiological process preserved in multiple sclerosis. Neuroimage 2008 0.89
73 Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials. Neurology 2005 0.89
74 Proton MRS of gadolinium-enhancing MS plaques and metabolic changes in normal-appearing white matter. Magn Reson Med 1995 0.88
75 Gelatinase B [matrix metalloproteinase (MMP)-9] and collagenases (MMP-8/-13) are upregulated in cerebrospinal fluid during aseptic and bacterial meningitis in children. Neuropathol Appl Neurobiol 2006 0.88
76 Combined acute disseminated encephalomyelitis and acute motor axonal neuropathy after vaccination for hepatitis A and infection with Campylobacter jejuni. J Neurol 1999 0.88
77 Escalating immunotherapy of multiple sclerosis--new aspects and practical application. J Neurol 2004 0.88
78 Balancing the Th1/Th2 concept in multiple sclerosis. Immunol Today 1998 0.88
79 Lesional magnetization transfer ratio: a feasible outcome for remyelinating treatment trials in multiple sclerosis. Mult Scler 2010 0.87
80 Evoked potentials for evaluation of multiple sclerosis. Clin Neurophysiol 2001 0.87
81 T cell receptor gamma delta repertoire is skewed in cerebrospinal fluid of multiple sclerosis patients: molecular and functional analyses of antigen-reactive gamma delta clones. Eur J Immunol 1995 0.87
82 Interferon beta-1b treatment does not induce autoantibodies. Neurology 2005 0.87
83 The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS. Neurology 2003 0.86
84 Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study. Mult Scler 2004 0.86
85 Indication for psychotherapy in offspring of a parent affected by a chronic somatic disease (e.g. multiple sclerosis). Psychopathology 2005 0.85
86 MRI study of Baló's concentric sclerosis before and after immunosuppressive therapy. J Neurol 1989 0.85
87 Infusion-related hypersensitivity reactions during natalizumab treatment. Neurology 2006 0.85
88 Gangliosides and autoimmune neuropathies: classification and clinical aspects of autoimmune neuropathies. J Neurol Neurosurg Psychiatry 1994 0.85
89 [Cerebral and spinal MRI examination in patients with clinically isolated syndrome and definite multiple sclerosis]. Rofo 2008 0.84
90 Pooled historical MRI data as a basis for research in multiple sclerosis--a statistical evaluation. Mult Scler 2007 0.84
91 Neuropsychological dysfunction, depression, physical disability, and coping processes in families with a parent affected by multiple sclerosis. Mult Scler 2008 0.84
92 Pattern of macular thickness changes measured by ocular coherence tomography in patients with multiple sclerosis. Klin Monbl Augenheilkd 2008 0.84
93 Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials. J Neurol 1997 0.84
94 Proof of concept studies for tissue-protective agents in multiple sclerosis. Mult Scler 2009 0.83
95 The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS. Neurology 2001 0.82
96 Gender effects on intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: analysis of 1406 patients. Mult Scler 2010 0.82
97 Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: a consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation. BMT-MS Study Group. J Neurol 2000 0.82
98 T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. Brain 2001 0.82
99 Single-dose gadolinium with magnetization transfer versus triple-dose gadolinium in the MR detection of multiple sclerosis lesions. AJNR Am J Neuroradiol 1997 0.81
100 Gender-specific differences in the process of coping in families with a parent affected by a chronic somatic disease (e.g. multiple sclerosis). Psychopathology 2002 0.81
101 Disease variables and depression affecting the process of coping in families with a somatically ill parent. Psychopathology 2007 0.81
102 Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis. Mult Scler 2011 0.80
103 Rigidity of retinal vessels in patients with multiple sclerosis. Klin Monbl Augenheilkd 2009 0.80
104 Classification of patients with a clinically isolated syndrome based on signs and symptoms is supported by magnetic resonance imaging results. Mult Scler 2007 0.80
105 Interleukin 15 stimulates production of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by human peripheral blood mononuclear cells. Cytokine 2001 0.80
106 Evaluation of a computer-based attention retraining program for patients with multiple sclerosis. Schweiz Arch Neurol Psychiatr 1994 0.80
107 Swallowing abnormalities in multiple sclerosis: correlation between videofluoroscopy and subjective symptoms. Eur Radiol 2001 0.80
108 Myelin-specific T lymphocytes in multiple sclerosis patients and healthy individuals. J Neuroimmunol 1988 0.80
109 Interferon beta-1b in secondary progressive multiple sclerosis--outline of the clinical trial. Mult Scler 1995 0.79
110 Hereditary defect of cobalamin metabolism (homocystinuria and methylmalonic aciduria) of juvenile onset. J Neurol Neurosurg Psychiatry 1996 0.79
111 Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study. Mult Scler 2003 0.79
112 Evaluation of soluble HLA-G as a biomarker for multiple sclerosis. Neurology 2011 0.79
113 Qualitative and quantitative analysis of antibody response against IFNbeta in patients with multiple sclerosis. Mult Scler 2006 0.79
114 A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine. Int J Clin Pract 2000 0.78
115 Effects of inhibitors of the renin-angiotensin system on the efficacy of interferon beta-1b: a post hoc analysis of the BEYOND study. Eur Neurol 2014 0.78
116 Genetic associations with brain cortical thickness in multiple sclerosis. Genes Brain Behav 2015 0.78
117 A randomized, double-blind, placebo-controlled study of oral hydrolytic enzymes in relapsing multiple sclerosis. Mult Scler 2005 0.78
118 ["Numb chin syndrome": first presenting syndrome of multiple sclerosis?]. Dtsch Med Wochenschr 2008 0.78
119 Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis. Mult Scler 2000 0.77
120 Retinal vessels in patients with multiple sclerosis: baseline diameter and response to flicker light stimulation. Klin Monbl Augenheilkd 2009 0.77
121 Six-year follow-up of a case series with non-communicating syringomyelia in multiple sclerosis. Eur J Neurol 2012 0.77
122 Occurrence of MRI abnormalities in patients with isolated optic neuritis. Eur Neurol 1990 0.77
123 Can the functional assessment of multiple sclerosis adapt to changing needs? A psychometric validation in patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis. Mult Scler 2011 0.77
124 Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosis. Eur J Neurol 2005 0.77
125 Reconsidering clinical outcomes in Multiple Sclerosis: relapses, impairment, disability and beyond. J Neurol Sci 2008 0.77
126 No influence of KIF1B on neurodegenerative markers in multiple sclerosis. Neurology 2011 0.77
127 [Interferon beta-1b for treatment of secondary chronic progressive multiple sclerosis]. Nervenarzt 1999 0.76
128 Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2003 0.76
129 Longitudinal spatiotemporal distribution of gray and white matter pathology in multiple sclerosis. AJNR Am J Neuroradiol 2010 0.76
130 Progression of gray matter atrophy and its association with white matter lesions in relapsing-remitting multiple sclerosis. J Neurol Sci 2009 0.76
131 Multiple Sclerosis Severity Scale and whole-brain N-acetylaspartate concentration for patients' assessment. Mult Scler 2011 0.76
132 Intravenous immunoglobulin (IVIG) treatment for patients with primary or secondary progressive multiple sclerosis -- outline of a double-blind randomized, placebo-controlled trial. Mult Scler 1997 0.75
133 Development of multiple sclerosis in patient on long-term sulfasalazine. Lancet 1990 0.75
134 [Multiple sclerosis. Current review of failed and discontinued clinical trials of drug treatment]. Nervenarzt 2000 0.75
135 Intracranial aneurysms. N Engl J Med 1997 0.75
136 Search for retroviral sequences in peripheral blood mononuclear cells and brain tissue of multiple sclerosis patients. J Neurol 1990 0.75
137 Multiple sclerosis trials. Lancet 1999 0.75
138 Interferon beta-1a and beta-1b for treatment of multiple sclerosis. Lancet 2002 0.75
139 Re: Short-term brain atrophy changes in relapsing-remitting multiple sclerosis. J Neurol Sci 2005 0.75
140 MRI and assessment of treatment in multiple sclerosis. Brain 2001 0.75
141 The use of magnetic resonance imaging in multiple sclerosis treatment trials: power calculations for annual lesion load measurement. J Neurol 2000 0.75
142 Contributions of magnetic resonance imaging to the diagnosis of MS in isolated optic neuritis. Psychiatry Res 1989 0.75
143 Expression of the B cell-associated tyrosine kinase gene Lyn in primary neuroblastoma tumours and its modulation during the differentiation of neuroblastoma cell lines. Biochem Biophys Res Commun 1992 0.75
144 Database for serial magnetic resonance imaging in multiple sclerosis. Neuroradiology 1993 0.75
145 Heterologous gene expression of a novel brain-specific protein tyrosine kinase. Schweiz Arch Neurol Psychiatr 1994 0.75
146 Correlation of MRI findings and neuropsychological results in patients with multiple sclerosis. Psychiatry Res 1989 0.75
147 Fatal vascular leak syndrome with extensive hemorrhage, peripheral neuropathy and reactive erythrophagocytosis: an unusual complication of recombinant IL-3 therapy. Leuk Lymphoma 1996 0.75
148 [Reversible dementia]. Praxis (Bern 1994) 1998 0.75
149 [Stress-related vertical double vision and ptosis]. Ophthalmologe 2009 0.75
150 Protein kinases expressed in aggregating brain cell cultures during myelination. Schweiz Arch Neurol Psychiatr 1993 0.75
151 Multiple sclerosis and human T-cell lymphotropic retroviruses: negative serological results in 135 German patients. J Neurol 1987 0.75
152 [Early summer meningoencephalitis vaccination. The indications and a critical assessment of the neurological vaccination complications]. Dtsch Med Wochenschr 1992 0.75
153 The contribution of magnetic resonance imaging in the differential diagnosis of the damage of the cerebral hemispheres. J Neurol Sci 2000 0.75
154 [Late manifestation of radiation injury to the plexus brachialis and plexus lumbosacralis]. Schweiz Med Wochenschr 2000 0.75
155 [Diagnosis and differential diagnosis in multiple sclerosis]. Praxis (Bern 1994) 1997 0.75
156 [Data on the structure of neurologic inpatient care centers in West Germany]. Nervenarzt 1982 0.75
157 Use of composite scores in the quantification of deterioration in multiple sclerosis. Mult Scler 1999 0.75
158 [Hereditary motor and sensory neuropathies. Clinical and molecular genetic aspects]. Schweiz Arch Neurol Psychiatr 1995 0.75
159 Bimonthly assessment of magnetization transfer magnetic resonance imaging parameters in multiple sclerosis: a 14-month, multicentre, follow-up study. Mult Scler 2010 0.75
160 Lack of association between antiphospholipid antibodies and migraine. Thromb Haemost 1993 0.75
161 [Neurological complications of HIV infection. Review: new diagnostic, therapeutic and prognostic aspects]. Schweiz Med Wochenschr 2000 0.75
162 [Multiple sclerosis: therapy with recombinant beta-1b interferon: initial results with 30 multiple sclerosis patients in northwest Switzerland]. Schweiz Med Wochenschr 1996 0.75
163 [Multiple sclerosis and its delimitation from other diseases. Case report examples with differential diagnostic considerations]. Med Klin (Munich) 1990 0.75
164 [Results of the 2d study on the structure of neurologic inpatient facilities in West Germany]. Nervenarzt 1986 0.75
165 [MRI follow-up in multiple sclerosis. A guideline for quality assurance]. Rofo 1999 0.75
166 Body fluid markers to monitor multiple sclerosis: the assays and the challenges. Mult Scler 1998 0.75
167 Meningoradiculitis associated with giant cell arteritis. Neurology 2002 0.75
168 [Adrenoleukodystrophy: the significance of peroxisomal disease in adult neurology]. Nervenarzt 1990 0.75
169 [Sclerotic plaques and hepatitis B vaccination in adults: the situation in 2004. Response]. Rev Neurol (Paris) 2005 0.75
170 [Comments on outpatient psychiatric-psychotherapeutic treatment by practising neurologist (author's transl)]. Psychother Psychosom Med Psychol 1981 0.75
171 [Diagnosis and therapy of polyneuropathy in old age]. Schweiz Rundsch Med Prax 1991 0.75